| Whole-body tyrosine flux in relation to energy expenditure in weight-losing cancer patients. | |
| | |
MedLine Citation:
|
PMID: 6493045 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Whole-body tyrosine flux was measured in seven weight-losing cancer patients and compared with that of seven noncancer patients with malnutrition. L[U-14C] tyrosine was infused intravenously (IV) after an overnight fast under resting conditions and flux rates, oxidation, and incorporation into proteins of tyrosine were calculated from plateau values of specific activity of tyrosine in plasma and of labeled expired carbon dioxide. Rates of protein synthesis were calculated from the flux rate of tyrosine after subtracting the proportion oxidized. Simultaneous measurements of whole-body carbon dioxide production and oxygen uptake were also performed in each subject. Cancer patients had elevated whole-body tyrosine flux, protein synthesis, and energy expenditure when expressed in relation to body weight and whole-body potassium while the differences in tyrosine kinetics became of borderline significance when expressed in relation to energy expenditure. Tyrosine incorporation into whole-body proteins corresponded to a synthesis rate of 2.70 +/- 0.17 protein/kg/d in cancer patients and 2.18 +/- 0.17 in control patients (P less than 0.025). The results show that elevated protein synthesis in weight-losing cancer patients may explain not more than one third of the elevated energy expenditure. Therefore, other systems that utilize energy must increase in activity. |
| | |
Authors:
|
E Edén; L Ekman; K Bennegård; L Lindmark; K Lundholm |
Related Documents
:
|
7352315 - Excessive caloric expenditure as a cause of malnutrition in patients with cancer. 20299525 - Wheel running, skeletal muscle aerobic capacity and 1-methyl-1-nitrosourea induced mamm... 7104955 - Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling ... 16214835 - Cancer cachexia. 11057785 - Hydronephrosis and renal deterioration in the elderly due to abnormalities of the lower... 14755895 - Technology evaluation: pegaptanib, eyetech/pfizer. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: 33 ISSN: 0026-0495 ISO Abbreviation: Metab. Clin. Exp. Publication Date: 1984 Nov |
Date Detail:
|
Created Date: 1984-12-03 Completed Date: 1984-12-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1020-7 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Body Weight* Energy Metabolism* Humans Kinetics Middle Aged Neoplasms / complications, metabolism* Nutrition Disorders / etiology, metabolism Oxygen Consumption Protein Biosynthesis Tyrosine / metabolism* |
| Chemical | |
Reg. No./Substance:
|
55520-40-6/Tyrosine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dietary omega-3 fatty acids prevent carbohydrate-induced hypertriglyceridemia.
Next Document: 3'-Monoiodothyronine degradation in rat liver homogenate: enzyme characteristics and documentation o...